ARHGEF17

Across TCGA pan-cancer cohorts, ARHGEF17 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated ARHGEF17 data layer compared with 6 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ARHGEF17 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF17 expression acts as an unfavorable survival marker, although some lineages such as KIRC and LGG show a favorable association.

LUSC, KIRC, and BLCA are the cancer types where ARHGEF17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Quartile	II,III,IV	0.632	0.844	<.001	86	view →
KIRC	DFS	Median	All	0.763	0.486	<.001	57	view →
BLCA	OS	Tertile	II,III,IV	0.345	0.594	.001	56	view →
LGG	DFS	Median	All	0.810	0.662	<.001	46	view →
OV	OS	Median	All	0.265	0.372	<.001	44	view →
COAD	DFS	Quartile	All	0.552	0.740	<.001	38	view →
CESC	DFS	Tertile	All	0.771	0.908	<.001	30	view →
UCS	OS	Quartile	II,III,IV	0.665	0.243	.023	28	view →
UCEC	DFS	Quartile	IV	0.842	0.264	<.001	24	view →
BRCA	OS	Quartile	III,IV	0.678	0.220	.004	23	view →
HNSC	OS	Tertile	III,IV	0.560	0.876	<.001	20	view →
LUAD	OS	Tertile	II,III,IV	0.566	0.345	.013	20	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

ARHGEF17–LUSC (DFS)

Open the LUSC breakdown →